Banking

I-Mab Stock Flashes Vital Signs With 89 RS Rating

I-Mab (IMAB) had its Relative Strength Rating upgraded from 70 to 89 on Wednesday. Is I-Mab stock on your radar?




X



When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.

This exclusive rating from Investor’s Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock’s price behavior over the trailing 52 weeks holds up against all the other stocks in our database.

Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves. So the 89 RS Rating for I-Mab stock is noteworthy.


Looking For Winning Stocks? Try This Simple Routine


Is I-Mab Stock In The Buy Zone?

I-Mab stock is trying to complete a consolidation with an 85.50 entry. See if I-Mab stock can break out in heavy trading. It’s a later-stage pattern, and investors should be aware that those involve more risk.

Earnings growth for the clinical-stage biopharma company worsened last quarter from flat to -79%. But sales growth dramatically improved, from -100% to 5,528%.

I-Mab stock earns the No. 65 rank among its peers in the Medical-Biomed/Biotech industry group. Maravai LifeSciences (MRVI) and BioNTech (BNTX) are also among the group’s highest-rated stocks.

YOU MIGHT ALSO LIKE:

Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button